Compare WKEY & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | ONCY |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.4M | 94.0M |
| IPO Year | N/A | 1999 |
| Metric | WKEY | ONCY |
|---|---|---|
| Price | $8.56 | $1.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $10.50 | $6.00 |
| AVG Volume (30 Days) | 194.2K | ★ 1.0M |
| Earning Date | 09-23-2025 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,994,000.00 | N/A |
| Revenue This Year | $32.29 | N/A |
| Revenue Next Year | $89.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.50 | $0.33 |
| 52 Week High | $19.80 | $1.51 |
| Indicator | WKEY | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 66.44 |
| Support Level | $8.10 | $0.98 |
| Resistance Level | $9.37 | $1.30 |
| Average True Range (ATR) | 0.69 | 0.08 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 37.13 | 84.21 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.